Literature DB >> 21376154

Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Robert F Ashman1, J Adam Goeken, Petar S Lenert.   

Abstract

Toll-like receptor 9 (TLR9) is an endosomal DNA sensor that warns us of the presence of infectious danger and triggers a rapid pro-inflammatory response in dendritic cells, macrophages, and B cells. The consequences of uncontrolled TLR9 activation can be detrimental for the host, contributing to the pathogenesis of bacterial septic shock or autoimmune diseases, such as systemic lupus erythematosus. Therefore, we need to develop TLR9 antagonists. We and others have created inhibitory oligonucleotides (INH-ODN) that are capable of sequence-dependent inhibition of TLR9-induced activation in both human and mouse cells. However, it is not clear whether marked differences in INH-ODN activity related to base sequence derived from polymerization of INH-ODNs or their ability to complex with stimulatory CpG-oligonucleotides (ST-ODN). Furthermore, the 5' end of INH-ODNs may assume a particular loop configuration that may be needed for binding to a critical site on TLR9. Here, we show that 1) G-tetrads required for ODN stacking were compatible with INH-ODN activity but were not necessary; 2) there was no relationship between activity and self-association at endosomal pH; 3) there was no evidence for direct binding between ST-ODNs and INH-ODNs; 4) when a 3G sequence was disrupted, despite a preserved stem-loop formation, INH-ODN activity was abolished. These results support the conclusion that certain features of the primary linear sequence are critical for TLR9 inhibition, but changes in secondary structure or in ODN aggregation are irrelevant.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376154      PMCID: PMC3119753          DOI: 10.1016/j.intimp.2011.02.023

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  41 in total

1.  Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.

Authors:  Y Chen; P Lenert; R Weeratna; M McCluskie; T Wu; H L Davis; A M Krieg
Journal:  Gene Ther       Date:  2001-07       Impact factor: 5.250

Review 2.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway.

Authors:  A K Yi; D W Peckham; R F Ashman; A M Krieg
Journal:  Int Immunol       Date:  1999-12       Impact factor: 4.823

4.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells.

Authors:  Laura L Stunz; Petar Lenert; David Peckham; Ae-Kyung Yi; Sokol Haxhinasto; Ming Chang; Arthur M Krieg; Robert F Ashman
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

6.  CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.

Authors:  P Lenert; L Stunz; A K YI; A M Krieg; R F Ashman
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-08

7.  Inhibition of murine macrophage IL-12 production by natural and synthetic DNA.

Authors:  D S Pisetsky; C F Reich
Journal:  Clin Immunol       Date:  2000-09       Impact factor: 3.969

8.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

9.  Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding.

Authors:  Robert F Ashman; J Adam Goeken; Eicke Latz; Petar Lenert
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

10.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

View more
  2 in total

Review 1.  Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.

Authors:  Damir Matesic; Aleksander Lenert; Petar Lenert
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

2.  Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.

Authors:  Franziska Römmler; Monika Hammel; Anna Waldhuber; Tina Müller; Marion Jurk; Eugen Uhlmann; Hermann Wagner; Jörg Vollmer; Thomas Miethke
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.